Is bortezomib active in patients with mantle cell lymphoma?

被引：0
|
作者：
Ludwig, Heinz [1 ]
机构：
[1] Wilhelminenspital Stadt Wien, Dept Med 1, Ctr Oncol & Haematol, A-1171 Vienna, Austria
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2007年 / 4卷 / 05期
关键词：
bortezomib; mantle cell lymphoma; response; toxicity;
D O I：
10.1038/ncponc0789
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：276 / 277
页数：2
相关论文
共 50 条
  • [31] Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance
    Kim, Areumnuri
    Seong, Ki Moon
    Kang, Hye Jin
    Park, Sunhoo
    Lee, Seung-Sook
    ONCOTARGET, 2015, 6 (35) : 38225 - 38238
  • [32] Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma
    Leshchenko, Violetta V.
    Kuo, Pei-Yu
    Jiang, Zewei
    Weniger, Marc A.
    Overbey, Jessica
    Dunleavy, Kieron
    Wilson, Wyndham H.
    Wiestner, Adrian
    Parekh, Samir
    ONCOTARGET, 2015, 6 (29) : 27332 - 27342
  • [33] Mantle Cell-Lymphoma Bortezomib effective also in the Induction Therapy
    Weiss, Johannes
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2015, 140 (09) : 640 - 640
  • [34] Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma
    Jung, Hyun Joo
    Chen, Zheng
    McCarty, Nami
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (12) : 1057 - 1064
  • [35] PRDM1 Is Required for Mantle Cell Lymphoma Response to Bortezomib
    Desai, Shruti
    Maurin, Michelle
    Smith, Matthew A.
    Bolick, Sophia C. E.
    Dessureault, Sophie
    Tao, Jianguo
    Sotomayor, Eduardo
    Wright, Kenneth L.
    MOLECULAR CANCER RESEARCH, 2010, 8 (06) : 907 - 918
  • [36] Activity of bortezomib in mantle cell lymphoma, diffuse large B cell, and small lymphocytic lymphoma.
    Fauble, Veena S.
    Lobocki, Catherine
    Eapen, Amy
    Terebelo, Howard R.
    BLOOD, 2006, 108 (11) : 252B - 252B
  • [37] Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): Preliminary results of the PINNACLE study.
    Goy, A
    Bernstein, S
    Kahl, B
    Epner, E
    Leonard, JP
    Stadtmauer, E
    Morgan, D
    Belt, R
    Baidas, S
    Fisher, RI
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 575S - 575S
  • [38] BORTEZOMIB AND BEAM CONDITIONING REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MANTLE CELL LYMPHOMA
    Hebraud, B.
    Roussel, M.
    Ysebaert, L.
    Gaudin, C.
    Laurent, G.
    Attal, M.
    Huynh, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 462 - 463
  • [39] Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular and mantle cell lymphoma
    O'Connor, Owen A.
    ANNALS OF ONCOLOGY, 2004, 15 : 152 - 152
  • [40] Resistance to bortezomib in mantle cell lymphoma is associated with differentiation towards a plasma cell phenotype
    Perez-Galan, Patricia
    Mora-Jensen, Helena
    Weniger, Marc
    Chapman, Colby
    Wiestner, Adrian
    CANCER RESEARCH, 2009, 69
12345